Biotherapy of chronic myelogenous leukemia

Annals of Hematology

Volumn 70, Issue 3, 1995, Pages 113-120

  Aulitzky, W E ^a   Peschel, C ^a   Schneller, F ^a   Huber, C ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Bone marrow transplantation; CML; IFN alpha

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYTARABINE; HYDROXYUREA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANOREXIA; AUTOIMMUNITY; BLOOD TOXICITY; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOLOGY; CYTOPENIA; DEPRESSION; DISEASE COURSE; DRUG MECHANISM; DRUG TOXICITY; GROWTH INHIBITION; HEARING IMPAIRMENT; HEMATOLOGY; HUMAN; LEUKEMIA REMISSION; LIVER TOXICITY; MALAISE; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK; SIDE EFFECT; SURVIVAL;

HUMAN; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC;

EID: 0028910764     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/BF01682030     Document Type: Review

References (80)

1. Secondary chromosome changes in chronic myeloid leukemia
2. Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results
3. Interferon alpha prolongs survival for patients with CML in chronic phase: preliminary results of the UK MRC randomized multicenter trial (abstract)
4. Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells
5. Outcome for patients who relapse after allogenic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group
6. Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia
7. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study [see comments]
8. The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene
9. The involvement of “tumor suppressor” p53 in normal and chronic myelogenous leukemia hemopoiesis
10. 1993 progress report from the international bone marrow transplant registry
11. Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: preliminary results of an open French multicentre randomized study
12. Comparative analyses of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte macrophage (CFU-GM) progenitor cells
13. Exacerbation of symptoms of autoimmune disease in patients receiving IFN alpha therapy
14. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis
15. The effects of interferon-alpha on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint
16. Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells
17. Suppression of chronic myelogenous leukemia colony growth by interleukin-4
18. Initiation and progression of chronic myelogenous leukemia
19. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte platelet and monocyte/macrophage
20. Proliferation of myeloid progenitor cells in human long-term bone marrow cultures is stimulated by interleukin-1 beta
21. Recombinant human Interferon (IFN)-alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies
22. Combination of chemotheraphy and interferon-alpha-2b in the treatment of chronic myelogenous leukemia
23. Genetic analysis of p53 and RB1 tumorsuppressor genes in blast crisis of chronic myeloid leukemia
24. Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors
25. Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response
26. Bone marrow transplantation for chronic myelogenous leukemia
27. Altered adhesive interaction with bone marrow stroma of haematopoetic progenitor cells in chronic myelogenous leukemia
28. Deficiency of a phosphatidylinositol-anchored cell adhesion molecule influences haemopoietic progenitor binding to marrow stroma in chronic myeloid leukaemia
29. A differential sensitivity to recombinant human interferon-alpha-2a between normal and chronic myeloid leukaemic peripheral blood granulocyte-macrophage colony-forming units
30. Interferon-alpha and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group
31. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia (Abstract)
32. Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia
33. Interferon-alpha-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic-phase CML previously resistant to therapy with interferongamma
34. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation
35. Use of interferon alpha-2a to treat hematologic relapse of chronic myelogenous leukemia after bone marrow transplantation
36. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia
37. Sudden hearing loss associated with interferon
38. Chronic myeloid leukemia in blast crisis: an analysis of 242 patients
39. Chronic myelogenous leukemia: a concise update
40. Synthesis of granulocyte colony-stimulating factor and its requirement for terminal divisions in chronic myelogenous leukemia
41. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected; published erratum appears in Bloo 1992 Jun 15; 79:3397]
42. Combination therapy for chronic myelogenous leukemia with interferon alpha and other cytokines
43. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia
44. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
45. Adoptive immunotherapy in human and canine chimeras — the role of interferon alpha. EBMT Chronic Leukemia Working Party
46. An alteration of the human c-abl protein in K562 cells unmasks associated tyrosine kinase activity
47. Clonal evolution in a myeloid cell line transformed to interleukin-3-independent growth by retroviral transduction and expression of p210bcr/abl
48. Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion
49. Activation of tyrosinase ki-nase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins
50. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias
51. Evolving modalities of treatment with interferon alpha-2b for Ph1-positive chronic myelogenous leukaemia
52. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction-based techniques
53. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies
54. Prophylactic use of interferon alpha after bone marrow transplantation for patients with chronic myelogenous leukemia at high risk of relapse: a pilot study. The Chronic Leukemia Working Party of the EBMT
55. A minute chromosome in human granulocytic leukemia
56. Prolonged subcutaneous administration of recombinant alpha-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583
57. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
58. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia
59. Autologous blood stem-cell transplantation and recombinant interferon alpha in chronic myeloid leukemia
60. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining
61. Sequential treatment of Ph-positive chronic myeloid leukemia with interferon gamma and interferon alpha
62. Immune-mediated and unusual complications during interferon alpha therapy in chronic myelogenous leukemia (Abstract)
63. Recombinant interferon beta ser protects against zidovidine-induced genetic damage in AIDS patients
64. Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia
65. Influence of acute and chronic graft-versus-host disease on relapse survival after bone marrow transplantation from HLA identical siblings as treatment of acute and chronic leukemia
66. Leukocyte interferon induced myeloid cytoreduction in chronic myelogenous leukemia
67. Clinical investigation of human interferon alpha in chronic myelogenous leukemia
68. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients
69. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway
70. Rekombinantes Interferon alpha-2c bei Phi-positiver chronischer myeloischer Leukämie
71. Treatment of chronic myelogenous leukemia with interferon alpha-2c: response rate and toxicity in a phase-II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group
72. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients
73. Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukemia in chronic phase: a comparison of transplant versus no-transplant in a cohort of 258 patients first seen in Italy between 1984 and 1986
74. Low frequency of ras oncogene mutations in Philadelphia-positive acute leukemia and report of a novel mutation H61 Leu in a single case
75. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse
76. Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia
77. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative discorders
78. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression